Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed EPS (Basic) for 10 consecutive years, with -$1.28 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 7.25% to -$1.28 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.83 through Dec 2025, up 7.9% year-over-year, with the annual reading at -$5.83 for FY2025, 7.31% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$1.28 at Ultragenyx Pharmaceutical, up from -$1.81 in the prior quarter.
  • The five-year high for EPS (Basic) was -$1.08 in Q3 2021, with the low at -$3.5 in Q3 2022.
  • Average EPS (Basic) over 5 years is -$1.86, with a median of -$1.81 recorded in 2021.
  • The sharpest move saw EPS (Basic) plummeted 530.95% in 2021, then soared 37.22% in 2024.
  • Over 5 years, EPS (Basic) stood at -$1.79 in 2021, then dropped by 20.67% to -$2.16 in 2022, then soared by 33.33% to -$1.44 in 2023, then rose by 4.17% to -$1.38 in 2024, then rose by 7.25% to -$1.28 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.28, -$1.81, and -$1.17 for Q4 2025, Q3 2025, and Q2 2025 respectively.